Symbols

NERV

Minerva·NASDAQ

--(--)

Signals Analysis

Bullish signal 1

Bearish signal 2

Ample Liquidity

Significant Net Income Decline

EPS Below Expectations

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About NERV

Minerva Neurosciences, Inc.

A clinical-stage biopharmaceutical company focused on the therapies to treat central nervous system disorders

Industry

Pharmaceutical

Established Date

04/23/2007

Listing Date

07/01/2014

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.minervaneurosciences.com

Security Type

Common stock

Office address

1500 District Avenue, Burlington, MA 01803

Business

Introduction

Minerva Neurosciences, Inc., was incorporated under the laws of the State of Delaware on April 23, 2007. The Company is a clinical-stage biopharmaceutical company focused on the development and commercialization of patented product candidates for central nervous system diseases. Its lead drug candidate, roluperidone, is in development for the treatment of negative symptoms of schizophrenia, with Phase 3 confirmatory trials planned.

Company Financials

EPS

NERV has released its 2025 Q4 earnings. EPS was reported at -0.64, versus the expected -0.11, missing expectations. The chart below visualizes how NERV has performed over recent quarters, highlighting trends in earnings surprises.